MedTrace Logo

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

NCT05126433 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2025-02-28

Study results available
· View outcomes & findings →

Summary

This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Urothelial Cancer
  • Poorly Differentiated Neuroendocrine Carcinomas
  • Homologous Recombination Deficient-Positive Malignancies Agnostic

Interventions

DRUG

Lurbinectedin

Lurbinectedin 3.2 mg/m\^2 intravenous (IV) every 3 weeks (Q3W)

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2023-12-20
Completion
2023-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05126433 on ClinicalTrials.gov